Cargando…

Overall Neutrophil-to-Lymphocyte Ratio and SUV(max) of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation

INTRODUCTION: This study investigates the pretherapeutic neutrophil-to-lymphocyte ratio (NLR) with markers of tumor metabolism in 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and their potential prognostic value in head and neck cancer patients prior to primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Werner, Jonas, Strobel, Klaus, Lehnick, Dirk, Rajan, Gunesh P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534919/
https://www.ncbi.nlm.nih.gov/pubmed/34692472
http://dx.doi.org/10.3389/fonc.2021.679287
_version_ 1784587659559043072
author Werner, Jonas
Strobel, Klaus
Lehnick, Dirk
Rajan, Gunesh P.
author_facet Werner, Jonas
Strobel, Klaus
Lehnick, Dirk
Rajan, Gunesh P.
author_sort Werner, Jonas
collection PubMed
description INTRODUCTION: This study investigates the pretherapeutic neutrophil-to-lymphocyte ratio (NLR) with markers of tumor metabolism in 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and their potential prognostic value in head and neck cancer patients prior to primary chemoradiation. MATERIALS AND METHODS: NLR and metabolic markers of primary tumor and nodal metastases including maximum standardized uptake value (SUV(max)), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were retrospectively assessed in a consecutive cohort of head and neck squamous cell cancer patients undergoing primary chemoradiation. The main outcome measure was survival. RESULTS: The study included 90 patients of which 74 had lymph node metastases at diagnosis. Median follow-up time of nodal positive patients (n=74) was 26.5 months (IQR 18–44). The NLR correlated significantly with metabolic markers of the primary tumor (TLG: r(s)=0.47, P<0.001; MTV: r(s)=0.40, P<0.001; SUV(max): r(s)=0.34, P=0.003), but much less with FDG-PET/CT surrogate markers of metabolic activity in nodal metastases (TLG: r(s)=0.15, P=0.19; MTV: r(s)=0.25, P=0.034; SUV(max): r(s)=0.06, P=0.63). For nodal positive cancer patients, multivariate analysis showed that an increased NLR (HR=1.19, 95% CI=1.04-1.37, P=0.012) and SUV(max) of lymph node metastasis (HR=1.09; 95% CI=0.99-1.19; P=0.081) are independently predictive of disease-specific survival. High NLR had a negative prognostic value for overall survival (HR=1.16, 95% CI=1.02-1.33, P=0.021). CONCLUSION: NLR correlates positively with metabolic markers of the primary tumor, suggestive of an unspecific inflammatory response in the host as a possible reflection of increased metabolism of the primary tumor. SUV(max) of lymph node metastases and the NLR, however, show no correlation and are independently predictive of disease-specific survival. Therefore, their addition could be used to improve survival prediction in nodal positive head and neck cancer patients undergoing primary chemoradiation.
format Online
Article
Text
id pubmed-8534919
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85349192021-10-23 Overall Neutrophil-to-Lymphocyte Ratio and SUV(max) of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation Werner, Jonas Strobel, Klaus Lehnick, Dirk Rajan, Gunesh P. Front Oncol Oncology INTRODUCTION: This study investigates the pretherapeutic neutrophil-to-lymphocyte ratio (NLR) with markers of tumor metabolism in 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and their potential prognostic value in head and neck cancer patients prior to primary chemoradiation. MATERIALS AND METHODS: NLR and metabolic markers of primary tumor and nodal metastases including maximum standardized uptake value (SUV(max)), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were retrospectively assessed in a consecutive cohort of head and neck squamous cell cancer patients undergoing primary chemoradiation. The main outcome measure was survival. RESULTS: The study included 90 patients of which 74 had lymph node metastases at diagnosis. Median follow-up time of nodal positive patients (n=74) was 26.5 months (IQR 18–44). The NLR correlated significantly with metabolic markers of the primary tumor (TLG: r(s)=0.47, P<0.001; MTV: r(s)=0.40, P<0.001; SUV(max): r(s)=0.34, P=0.003), but much less with FDG-PET/CT surrogate markers of metabolic activity in nodal metastases (TLG: r(s)=0.15, P=0.19; MTV: r(s)=0.25, P=0.034; SUV(max): r(s)=0.06, P=0.63). For nodal positive cancer patients, multivariate analysis showed that an increased NLR (HR=1.19, 95% CI=1.04-1.37, P=0.012) and SUV(max) of lymph node metastasis (HR=1.09; 95% CI=0.99-1.19; P=0.081) are independently predictive of disease-specific survival. High NLR had a negative prognostic value for overall survival (HR=1.16, 95% CI=1.02-1.33, P=0.021). CONCLUSION: NLR correlates positively with metabolic markers of the primary tumor, suggestive of an unspecific inflammatory response in the host as a possible reflection of increased metabolism of the primary tumor. SUV(max) of lymph node metastases and the NLR, however, show no correlation and are independently predictive of disease-specific survival. Therefore, their addition could be used to improve survival prediction in nodal positive head and neck cancer patients undergoing primary chemoradiation. Frontiers Media S.A. 2021-10-08 /pmc/articles/PMC8534919/ /pubmed/34692472 http://dx.doi.org/10.3389/fonc.2021.679287 Text en Copyright © 2021 Werner, Strobel, Lehnick and Rajan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Werner, Jonas
Strobel, Klaus
Lehnick, Dirk
Rajan, Gunesh P.
Overall Neutrophil-to-Lymphocyte Ratio and SUV(max) of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation
title Overall Neutrophil-to-Lymphocyte Ratio and SUV(max) of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation
title_full Overall Neutrophil-to-Lymphocyte Ratio and SUV(max) of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation
title_fullStr Overall Neutrophil-to-Lymphocyte Ratio and SUV(max) of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation
title_full_unstemmed Overall Neutrophil-to-Lymphocyte Ratio and SUV(max) of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation
title_short Overall Neutrophil-to-Lymphocyte Ratio and SUV(max) of Nodal Metastases Predict Outcome in Head and Neck Cancer Before Chemoradiation
title_sort overall neutrophil-to-lymphocyte ratio and suv(max) of nodal metastases predict outcome in head and neck cancer before chemoradiation
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534919/
https://www.ncbi.nlm.nih.gov/pubmed/34692472
http://dx.doi.org/10.3389/fonc.2021.679287
work_keys_str_mv AT wernerjonas overallneutrophiltolymphocyteratioandsuvmaxofnodalmetastasespredictoutcomeinheadandneckcancerbeforechemoradiation
AT strobelklaus overallneutrophiltolymphocyteratioandsuvmaxofnodalmetastasespredictoutcomeinheadandneckcancerbeforechemoradiation
AT lehnickdirk overallneutrophiltolymphocyteratioandsuvmaxofnodalmetastasespredictoutcomeinheadandneckcancerbeforechemoradiation
AT rajanguneshp overallneutrophiltolymphocyteratioandsuvmaxofnodalmetastasespredictoutcomeinheadandneckcancerbeforechemoradiation